Aneuploidy and prognosis of non-small-cell lung cancer: A meta-analysis of published data

British Journal of Cancer

Volumn 85, Issue 1, 2001, Pages 14-22

  Choma, D ^a   Daurès, J P ^b   Quantin, X ^a   Pujol, J L ^a,b  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

Non small cell lung cancer; Ploidy; Prognosis

Indexed keywords

ANEUPLOIDY; ARTICLE; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CELL HETEROGENEITY; CLINICAL TRIAL; DIPLOIDY; DNA CONTENT; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL TIME;

AGED; ANEUPLOIDY; CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PROGNOSIS;

EID: 0035816267     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.1892     Document Type: Article

References (73)

1. Histopathologic prognostic factors in resected adenocarcinomas
2. Prognostic significance of nuclear DNA content in mammary adenocarcinomas in humans
3. Cellular DNA content as a marker of neoplasia in man
4. Flow cytometry in clinical cancer research
5. Nuclear DNA measurements in squamous cell carcinoma of the lung: A guide for prognostic evaluation
6. Nuclear DNA content and behavior of oxyphil thyroid tumors
7. Diagnostic and biological implications of flow cytometry DNA content analysis in lung cancer
8. DNA content in correlation with post-surgical stage in non-small-cell lung cancer
9. Prognostic value and clinicopathologic correlation of p53 gene mutations and nuclear DNA content in human lung cancer: A prospective study
10. Flow cytometric analysis of DNA ploidy in primary non-small-cell carcinoma of the lung in Korea
11. Correlation between DNA content and amplification of oncogenes (c-myc, L-myc, c-erbB-2) and correlation with prognosis in 143 cases of resected lung cancer
12. The effect of tumor size and tumor cell DNA content on the survival of patients with stage 1 adenocarcmoma of the lung
13. p53 expression, DNA ploidy and S-pase cell fraction in operable locally advanced non-small-cell lung cancer
14. Prognostic indicators including DNA histogram type, receptor content, and staging related to human breast cancer patient survival
15. DNA aneuploidy, S-phase fraction, nuclear p53 positivity, and survival in non-small-cell lung carcinoma
16. DNA analysis by flow cytometry in non-small-cell lung cancer: Relationship to epidermal growth factor receptor, histology, tumour stage and survival
17. A prognostic model of survival in surgically resected squamous cell carcinoma of the lung using clinical, pathologic and biologic markers
18. Meta-analysis in clinical trials
19. Prognostic significance of tumor proliferative fraction and DNA content in stage I non-small-cell lung cancer
20. Clinical and biological significance of aneuploidy in human tumours
21. Influence of cellular DNA content on survival in advanced ovarian cancer
22. DNA flow cytometric analysis in patients with operable non-small-cell lung carcinoma
23. Blood group antigen A and flow cytometric analysis in resected early-stage non-small-cell lung cancer
24. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry
25. DNA ploidy and protein content in bronchioloalveolar carcinoma multi-variable flow cytometry
26. Postoperative adjuvant chemotherapy in non-small-cell lung cancer: Prognostic value of DNA ploidy and post-recurrent survival
27. Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small-cell lung cancer?
28. Use of high-resolution cytometry in predicting the biologic behavior of T1 adenocarcinoma of the lung
29. Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small-cell lung cancer
30. Valeur pronostique de la cytometrie en flux dans les cancers bronchiques epidermoides. Etude Retrospective a propos de 61 cas
31. Nonparametric estimation from incomplete observations
32. Clinical and flow cytometric prognostic factors in surgically treated squamous cell lung cancer
33. Cellular DNA content as a marker of human multiple myeloma
34. Prognostic value of deoxyribonucleic acid aneuploidy in primary non-small-cell lung carcinomas and their metastases
35. Analysis of prognostic factors in patients with resected peripheral T1 adenocarcinoma of the lung
36. Malignant potentiality of squamous cell carcinoma of the esophagus predictable by DNA content
37. Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer
38. DNA analysis of resected pulmonary adenocarcinoma
39. Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small-cell lung carcinomas
40. Prognostic value of flow cytometric DNA analysis in non-small-cell lung cancer: Rationale of sequential processing of frozen and paraffin-embedded tissue
41. Flow cytometric analysis of the DNA content of resected non-small-cell lung cancer with reference to long-term follow-up
42. Tumor cell instability, diversification, and progression to the metastatic phenotype: From oncogene to oncofetal expression
43. Prognostic implications of DNA histogram, DNA content, and histologic changes of regional lymph nodes in patients with lung cancer
44. Relationship between tumor DNA ploidy and regional lymph node changes in lung cancer
45. Image and flow cytometry of small cell carcinoma of the lung
46. Prognostic significance of the proliferation index in surgically resected non-small-cell lung cancer
47. Hypodiploidy, Ki-67 growth fraction and prognosis of surgically resected lung cancers
48. Prognostic significance of flow cytometry in non-small-cell lung cancer
49. Prognostic significance of DNA content in stage I adenocarcinoma of the lung
50. Flow cytometric analysis of the DNA content of non-small-cell lung cancer
51. DNA flow cytometric studies of 66 human lung tumors analyzed before treatment. Prognostic implications
52. The relevance of flow-cytometric DNA content in the evaluation of lung cancer
53. Intratumoral DNA content variability: A study of non-small-cell lung cancer
54. Results of surgical treatment of stage I lung cancer
55. Factors possibly affecting the degree of malignancy in adenocarcinoma of the lung. DNA content and Bromodeoxyuridine (Brdu) labeling index
56. Flow cytometric analysis of cellular DNA content of lung cancer with reference to survival
57. In situ evaluation of growth fraction determined by monoclonal antibody Ki-67 and ploidy in surgically resected non-small-cell lung cancers
58. Biclonal and hypodiploid multiple myeloma
59. Meta-analysis of the literature or of individual patient data: Is there a difference?
60. The importance of heterogeneity and of multiple site sampling in the prospective determination of deoxyribonucleic acid flow cytometry
61. Flow cytometric analysis of the DNA content of adenocarcinoma of the lung, especially for patients with stage I disease with long term follow-up
62. Flow cytometric analysis of DNA ploidy level in paraffin-embedded tissue of non-small-cell lung cancer
63. Prognostic significance of flow cytometry in lung cancer. A 5-year study
64. Flow cytometric analysis of nuclear DNA content of lung cancer. Correlation between nuclear DNA content and tumor doubling time
65. The percentage of aneuploidy cells is significantly correlated with survival in accurately staged patients with stage 1 resected squamous cell lung cancer and long term follow-up
66. High cell proliferation activity determined by DNA flow cytometry and prognosis in epidermoid lung carcinoma
67. DNA and S-phase distribution and incidence of metastasis in human primary lung carcinoma
68. Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small-cell lung carcinoma
69. DNA distribution in human colon carcinomas and its relationship to clinical behavior
70. The prognostic significance of nuclear DNA content in non-small-cell lung carcinoma
71. Flow cytometric DNA content and clinical outcome in patients with non-small-cell lung cancer given postoperative radiation therapy
72. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: Overview of results in mortality, reinfarction and side effects for 33 randomised clinical trials
73. Ploidy as a prognostic determinant in surgically treated lung cancer